| Market Cap | 50.47M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -71.08M | Forward P/E | -3.33 | EPS next Y | - | 50D Avg Chg | -15.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -33.00% |
| Dividend | N/A | Price/Book | 0.66 | EPS next 5Y | - | 52W High Chg | -71.00% |
| Recommedations | 3.00 | Quick Ratio | 1.12 | Shares Outstanding | 1.05M | 52W Low Chg | 24.00% |
| Insider Own | 36.40% | ROA | -19.42% | Shares Float | 594.38K | Beta | 97.48 |
| Inst Own | 10.77% | ROE | -191.03% | Shares Shorted/Prior | 9.36K/7.19K | Price | 2.90 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 15,070 | Target Price | - |
| Oper. Margin | - | Earnings Date | Nov 26 | Volume | 19,737 | Change | -2.36% |
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.